{"title":"Comparing cisplatin-Chemoradiotherapy to Cetuximab-radiotherapy in HPV<sup>+</sup> \"low-risk\" locally advanced oropharyngeal squamous cell carcinoma: lessons from De-escalate study.","authors":"Panagiota Economopoulou, Amanda Psyrri","doi":"10.1186/s41199-019-0040-5","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Human papillomavirus-associated oropharyngeal cancer (HPV-OSCC) is rapidly increasing in incidence and has unique epidemiologic, molecular, and biologic characteristics. Standard combined modality therapies for head and neck cancer confer a significant risk of morbidity. However, patients with HPV-OSCC are diagnosed at a younger age and have a superior prognosis; this spurs the development of treatment deintensification trials that attempt to decrease treatment-related morbidity without compromising efficacy.</p><p><strong>Main body: </strong>The De-Escalate-HPV is a randomized phase 3 study that compares the standard treatment, radiation and cisplatin, with radiation and epidermal growth factor receptor (EGFR) inhibitor cetuximab in patients with low-risk HPV-OSCC.</p><p><strong>Conclusion: </strong>In this commentary, we aim to discuss the results of the De-Escalate-HPV study.</p>","PeriodicalId":72518,"journal":{"name":"Cancers of the head & neck","volume":" ","pages":"1"},"PeriodicalIF":0.0000,"publicationDate":"2019-03-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1186/s41199-019-0040-5","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cancers of the head & neck","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1186/s41199-019-0040-5","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2019/1/1 0:00:00","PubModel":"eCollection","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
Background: Human papillomavirus-associated oropharyngeal cancer (HPV-OSCC) is rapidly increasing in incidence and has unique epidemiologic, molecular, and biologic characteristics. Standard combined modality therapies for head and neck cancer confer a significant risk of morbidity. However, patients with HPV-OSCC are diagnosed at a younger age and have a superior prognosis; this spurs the development of treatment deintensification trials that attempt to decrease treatment-related morbidity without compromising efficacy.
Main body: The De-Escalate-HPV is a randomized phase 3 study that compares the standard treatment, radiation and cisplatin, with radiation and epidermal growth factor receptor (EGFR) inhibitor cetuximab in patients with low-risk HPV-OSCC.
Conclusion: In this commentary, we aim to discuss the results of the De-Escalate-HPV study.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
